US hospital to start gene study for heart disease:
This article was originally published in Clinica
A hospital in Michigan is the latest centre to begin trials of a new treatment for heart disease which may trigger new vessels to grow and carry blood around blocked arteries. Patients at the Henry Ford Hospital will receive the growth factor VEGF (vascular endothelial growth factor), a naturally occurring protein secreted by heart tissue lacking oxygen which has been formulated by drugs firm Genentech. The treatment could replace some angioplasty or bypass surgery procedures.
You may also be interested in...
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.